Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)

Inclusion Criteria:

• Participant has provided informed consent prior to initiation of any study-specificactivities/procedures

• Age greater than or equal to 18 years old at the time of signing the informedconsent

• Histologically or cytologically confirmed SCLC. For parts A, C, D, E, F, and G:relapsed/refractory small cell lung cancer (R/R SCLC) who progressed or recurredfollowing platinum-based regimen

• Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

• Participants with treated brain metastases are eligible provided they meet definedcriteria

• Adequate organ function as defined in protocol

Exclusion Criteria:

• History of other malignancy within the past 2 years prior to first dose oftarlatamab with exceptions

• Major surgery within 28 days of first dose tarlatamab

• Untreated (includes new lesions or progression in previously treated lesions) orsymptomatic brain metastases and leptomeningeal disease (regardless of symptomaticor not).

• Prior anti-cancer therapy: at least 28 days must have elapsed between any prioranti-cancer therapy and first dose of tarlatamab with the following exceptions:participants who received conventional chemotherapy are eligible if at least 14 dayshave elapsed and if all treatment-related toxicity has been resolved to Grade lessthan or equal to 1; and prior palliative radiotherapy must have been completed atleast 7 days before the first dose of tarlatamab

• Participants who experienced severe, life-threatening or recurrent (Grade 2 orhigher) immune-mediated AEs or infusion-related reactions including those that leadto permanent discontinuation while on treatment with immune-oncology agents

• Has evidence of interstitial lung disease or active, non-infectious pneumonitis

• Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or anyother form of immunosuppressive therapy within 7 days prior to the first dose oftarlatamab

• Part C only: history of solid organ transplantation or active autoimmune diseasethat has required systemic treatment within the past 2 years

• Participant with symptoms and/or clinical signs and/or radiographic signs thatindicate an acute and/or uncontrolled active systemic infection within 7 days priorto the first dose of investigational product administration